Enanta Pharmaceuticals, Inc. (ENTA) Financials

ENTA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 314.7 million 198.1 million
Dec. 31, 2025 329.5 million 202.9 million
Sept. 30, 2025 280.7 million 216.0 million
June 30, 2025 301.0 million 221.8 million

ENTA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -7.2 million ?
Dec. 31, 2025 -11.8 million 3.8 million
Sept. 30, 2025 -7.9 million 4.0 million
June 30, 2025 17.4 million 4.2 million

ENTA Net Income

No data available :(

ENTA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 163.8 million 98.6 million 52.8 million
Dec. 31, 2025 185.8 million 104.1 million 57.1 million
Sept. 30, 2025 188.9 million 112.4 million 57.9 million
June 30, 2025 204.1 million 121.3 million 58.1 million

ENTA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 28.9 million
Dec. 31, 2025 21.4 million
Sept. 30, 2025 21.4 million
June 30, 2025 21.3 million

ENTA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 15000 19.4 million 9.6 million -
Dec. 31, 2025 143000 20.9 million 9.0 million -
Sept. 30, 2025 1.5 million 23.8 million 9.7 million -
June 30, 2025 155000 27.2 million 10.0 million -

ENTA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 17.2 million -
Dec. 31, 2025 18.6 million -
Sept. 30, 2025 15.1 million 1.3 million
June 30, 2025 18.3 million -

ENTA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ENTA

Price: $12.07

52 week price:
6.44
17.15

Earnings Per Share: -2.60 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 3045

Ebitda: 15.9 million

Market Capitalization: 272.3 million

Links: